Craniotomy — Cost, Top Hospitals & Success Rates | MyMedicPlus

Craniotomy is a foundational neurosurgical procedure in which a section of the skull (the bone flap) is temporarily removed to allow the neurosurgeon direct surgical access to the brain, its coverings (meninges), and the intracranial vasculature. Unlike craniectomy (where the bone is left out), in craniotomy the bone flap is carefully replaced and secured with titanium plates and screws at the conclusion of surgery, restoring the skull's protective and physiological functions. Craniotomy is the most common major neurosurgical procedure and serves as the platform for the majority of open intracranial operations.

The craniotomy approach is tailored to the specific intracranial target. Common approaches include: pterional craniotomy (frontotemporal) — the most versatile and frequently used approach, providing access to the anterior circulation aneurysms, temporal lobe, and Sylvian fissure; frontoparietal craniotomy — for frontal lobe tumours, anterior fossa pathology, and transcortical access; temporo-occipital craniotomy — for temporal and posterior fossa lateral pathology; parieto-occipital craniotomy — for the posterior parietal and visual cortex regions; retrosigmoid/suboccipital craniotomy — for posterior fossa tumours, acoustic neuroma (vestibular schwannoma), and posterior circulation aneurysms; and transcallosal/interhemispheric craniotomy — for midline structures including the third ventricle, pineal region, and corpus callosum.

Surgical planning uses high-resolution MRI and CT with frameless stereotactic neuronavigation — computer-assisted systems that use preoperative imaging registered to the patient's head position intraoperatively, providing the surgeon with real-time GPS-like localisation of the surgical target, critical structures, and tumour margins. Awake craniotomy, with the patient conscious during tumour removal, allows real-time cortical mapping — identifying eloquent cortex (speech and motor areas) that must be preserved to avoid neurological deficit. Intraoperative neurophysiological monitoring (somatosensory evoked potentials, motor evoked potentials) provides continuous safety feedback during surgery near functional cortex.

Craniotomy is performed for an extensive range of intracranial pathologies. Brain tumours — including gliomas (glioblastoma, astrocytoma, oligodendroglioma), meningiomas, metastatic deposits, pituitary adenomas (via transsphenoidal approach as an alternative), medulloblastomas, ependymomas, and vestibular schwannomas — represent the most common indication, with surgical resection (debulking or complete excision) providing tissue diagnosis, symptom relief, and in some tumours, improved survival. Spontaneous intracerebral haemorrhage (hypertensive basal ganglia bleeds, lobar haematomas, AVM bleeds, cavernous malformations) may require craniotomy for haematoma evacuation and underlying vascular lesion treatment.

Intracranial aneurysm clipping, arteriovenous malformation (AVM) resection, cerebral abscess drainage, subdural haematoma evacuation (acute or chronic — though burr holes suffice for many chronic SDH), epidural haematoma evacuation (urgent for symptomatic epidural bleeds), epilepsy surgery (resection of the epileptogenic focus — cortical resection, temporal lobectomy, hemispherectomy), and skull base surgery (for chordomas, glomus tumours, jugular foramen tumours, clivus lesions) are all performed through craniotomy approaches. Hydrocephalus management (endoscopic third ventriculostomy — ETV), CSF diversion, and placement of intraventricular chemotherapy reservoirs (Ommaya reservoir) are additional craniotomy-based procedures.

Craniotomy eligibility is determined primarily by the clinical indication (the severity and nature of the intracranial pathology) and the patient's ability to tolerate the procedure. For acute conditions (epidural haematoma, acute subdural haematoma causing herniation, cerebellar haemorrhage causing brainstem compression) — craniotomy is a life-saving emergency for which medical fitness is a secondary consideration. For elective procedures (brain tumour resection, elective aneurysm clipping, epilepsy surgery), comprehensive pre-operative assessment including general medical fitness (cardiovascular, pulmonary, hepatic, renal function), neurological status (Karnofsky Performance Status for tumour patients), imaging characteristics of the target lesion, and patient preference and understanding of risks and expected outcomes are all considered.

For brain tumours, surgical eligibility is guided by Karnofsky Performance Status (surgery generally not recommended below KPS 50), extent of resection achievable without unacceptable neurological risk (assessed by neuronavigation planning and fibre tractography), tumour location relative to eloquent cortex (assessed by fMRI and DTI tractography), and patient goals (preservation of quality of life vs maximum survival extension). Anticoagulants require perioperative bridging or cessation as directed by haematology consultation. Contraindications to craniotomy in elective settings include severely elevated coagulation risk, significant medical fitness issues, and patient refusal after fully informed consent.

Awake craniotomy with cortical mapping is the gold standard approach for tumours adjacent to eloquent cortex (primary motor, sensory, speech areas), allowing real-time functional monitoring during tumour removal to prevent permanent neurological deficit. The patient is anaesthetised for skull opening, then awakened for the cortical mapping and tumour resection phase, then re-anaesthetised for wound closure. This technique has been shown in multiple studies to increase the extent of tumour resection while reducing post-operative neurological morbidity.

Minimally invasive craniotomy using keyhole approaches — such as the supraorbital eyebrow craniotomy (providing anterior skull base access through a small incision), the retrosigmoid mini-craniotomy (for acoustic neuroma and posterior fossa pathology), and endoscope-assisted craniotomy — minimise scalp incision length, muscle dissection, and bone removal compared to traditional larger craniotomies, potentially reducing post-operative pain, hospital stay, and cosmetic impact. Intraoperative MRI-guided craniotomy, where a low-field or high-field MRI scanner within the operating room allows real-time imaging during tumour surgery, maximises the extent of glioma resection by identifying residual tumour before wound closure. Intraoperative neurophysiological monitoring — including motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and direct cortical stimulation — runs continuously throughout eloquent-area surgery to detect functional compromise before irreversible injury occurs, allowing the surgeon to modify the resection plane in real time. Navigation-guided resection using MRI or CT-based stereotactic systems provides millimetre-precise spatial orientation throughout the craniotomy.

For malignant brain tumours such as glioblastoma (GBM), maximum safe surgical resection (gross total resection or extent of resection >80%) is independently associated with improved overall survival — studies show median survival of 15+ months for gross total resection versus 10-12 months for biopsy-only in GBM treated with standard Stupp protocol (temozolomide and radiotherapy). Extent of resection is therefore a primary surgical goal. Meningiomas achieve cure (Simpson Grade I-II) with complete resection and dural base excision in over 90% of grade I meningiomas.

For intracerebral haematoma, craniotomy provides immediate relief of mass effect, brain decompression, and the opportunity to treat the underlying cause (AVM, cavernoma). Epilepsy surgery through temporal lobectomy or cortical resection achieves seizure freedom (Engel Class I) in 60-80% of carefully selected patients with mesial temporal lobe epilepsy or focal cortical dysplasia — a transformative outcome for patients with decades of intractable seizures. Acoustic neuroma (vestibular schwannoma) resection through the retrosigmoid or translabyrinthine approach provides decompression of the facial nerve and brainstem, with facial nerve preservation rates of 90%+ at experienced centres.

Craniotomy risks depend heavily on the specific procedure and the proximity of the surgical target to critical brain structures. General surgical risks include post-operative haematoma (epidural, subdural, or intracerebral — requiring re-operation in 2-5% of cases), wound infection (1-3%), meningitis, CSF leak (particularly in posterior fossa and skull base approaches), and deep vein thrombosis/pulmonary embolism (requiring chemoprophylaxis). Anaesthetic risks in prolonged neurosurgical procedures include positioning-related complications (visual loss from prone positioning, brachial plexus injury).

Procedure-specific neurological risks include: new or worsened motor deficit (weakness, hemiparesis) — reported in 5-20% depending on tumour location and extent of resection; aphasia (language impairment) in dominant hemisphere surgery — addressed by awake craniotomy technique; visual field defects from temporal lobe or occipital surgery; cranial nerve deficits from skull base surgery; cerebellar and brainstem deficits from posterior fossa surgery. Post-operative seizures occur in 5-15% and require antiepileptic management. Cerebral oedema post-operatively is managed with dexamethasone.

Post-craniotomy ICU or high-dependency monitoring for 24-48 hours is standard, with hourly neurological observation. Post-operative MRI within 24-72 hours confirms extent of tumour resection and excludes haematoma or ischaemia. Hospital discharge typically occurs at 3-7 days for straightforward craniotomies; longer for complex procedures with neurological complications. Gradual return to activities over 4-6 weeks; return to driving restricted until seizure-free for the required regulatory period (typically 6-12 months in most countries after neurosurgical intervention).

For tumour patients, oncological follow-up with neuro-oncology, radiation oncology, and medical oncology directs adjuvant treatment. MRI surveillance for tumour recurrence at 2-3 monthly intervals during active treatment, then 3-6 monthly intervals. Neurorehabilitation for residual neurological deficits — physiotherapy, speech therapy, occupational therapy, neuropsychological rehabilitation — begins as soon as the patient is medically stable. Epilepsy management requires long-term antiepileptic drugs and specialist neurology follow-up.

Craniotomy costs vary greatly by indication and complexity. In the USA, brain tumour craniotomy costs USD 40,000-120,000 including surgeon, hospitalisation, and anaesthesia; more complex procedures and extended ICU stays increase costs substantially. NHS in the UK provides craniotomy free of charge for all covered indications. Private craniotomy in the UK costs GBP 15,000-40,000.

India's neurosurgical centres — particularly NIMHANS, AIIMS, Apollo, Fortis, and Kokilaben hospitals — provide craniotomy at 40-60% of US private costs with fellowship-trained neurosurgeons and modern neuronavigation/intraoperative monitoring equipment. Brain tumour surgery in India at accredited hospitals costs USD 8,000-25,000 all-inclusive depending on tumour complexity. Medical tourism for brain tumour craniotomy to India is a growing sector for patients from Southeast Asia, Africa, and the Middle East seeking high-quality, affordable neurosurgical care.

For small brain tumours — particularly metastases, meningiomas, and acoustic neuromas below 3 cm — stereotactic radiosurgery (Gamma Knife, CyberKnife) delivers focused high-dose radiation to the tumour in a single session, achieving local control rates comparable to surgery for selected lesions without craniotomy. For some glioma presentations, biopsy alone (via stereotactic needle biopsy through a small burr hole) rather than resection is appropriate when the tumour is in eloquent location or the patient is medically unfit.

For intracerebral haematomas, medical management (blood pressure control, coagulopathy reversal, ICP management) is appropriate for many basal ganglia bleeds where surgical benefit is limited. Minimally invasive haematoma evacuation techniques — including MRI-guided stereotactic aspiration (Minimally Invasive Surgery and tPA for ICH Evacuation — MISTIE protocol) and endoscope-assisted minimally invasive surgery (ENRICH trial) — offer less invasive alternatives to craniotomy for haematoma removal that are increasingly supported by clinical trial evidence.